STAT+: Pharmalittle: We’re reading about a Purdue Pharma settlement, a setback for Merck and Eisai, and more

Top of the morning to you, and a fine one it is. Sunny skies and mild breezes are enveloping the Pharmalot campus once again.

And to celebrate, we are brewing another cuppa stimulation and inviting you to join us. Our choice today is blackberry hibiscus.

Remember, a prescription is not required. So no need to mess with rebates or even TrumpRx.

Meanwhile, here are a few items of interest. Hope you have a meaningful and productive day and, of course, do stay in touch.

… Pfizer executive Andrew Baum, a former analyst at Citibank who joined the drugmaker in June 2024 to redirect its strategic approach, has left his role as an executive vice president and chief strategy and innovation officer , STAT writes. He will continue as an adviser to Pfizer chief executive officer Albert Bourla until the end of the year.

Baum was part of a mini-trend of large pharmaceutical companies hiring former analysts at investment banks, who closely track multiple companies in order to help investors understand their businesses, as strategic leaders.